GlassScriptPhysician profile
Cynthia Walsh
NPI 1982898250
$4,625.70
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $453 · 2021: $633 · 2022: $632 · 2023: $1,067 · 2024: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.33 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.59 | 2019-2024 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $438.81 | 2021-2024 | |
| Novo Nordisk INC | $295.93 | 2019-2024 | Wegovy, Saxenda |
| Therapeuticsmd, INC. | $288.79 | 2020-2022 | |
| Astellas Pharma US INC | $286.00 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $265.86 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $260.93 | 2019-2022 | |
| Shield Therapeutics INC | $253.29 | 2024 | |
| Amgen INC. | $238.09 | 2019-2024 | Evenity, Prolia |
| Exact Sciences Corporation | $186.22 | 2023-2024 | Cologuard Collection Kit |
| Lupin INC. | $185.21 | 2019-2021 | |
| Organon LLC | $170.07 | 2021-2024 | Nexplanon |
| Currax Pharmaceuticals LLC | $127.31 | 2019-2023 | Contrave, Onzetra Xsail, Nexlizet |
| Sumitomo Pharma America, INC. | $112.39 | 2023-2024 | Myfembree, Gemtesa |
| Pfizer INC. | $96.50 | 2022-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $91.66 | 2019-2023 | Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $91.05 | 2024 | Slynd |
| Myovant Sciences INC. | $76.43 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $72.38 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $61.66 | 2020-2022 | |
| Roche Diagnostics Corporation | $55.66 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $50.91 | 2019 | |
| Duchesnay USA Incorporated | $48.94 | 2019 | |
| Myriad Women'S Health, INC. | $45.61 | 2023 | Myrisk |
| Minerva Surgical, INC | $43.64 | 2021-2024 | |
| Lilly USA, LLC | $30.26 | 2024 | Zepbound |
| Medline Industries LP | $29.86 | 2023 | |
| Evofem Biosciences, INC. | $27.87 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $23.90 | 2022 | |
| Abbott Laboratories | $22.37 | 2019 | |
| Allergan, INC. | $15.64 | 2020 | |
| Sage Therapeutics, LLC | $15.24 | 2024 | |
| Virtus Pharmaceuticals LLC | $14.20 | 2021 | |
| Becton, Dickinson and Company | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.